darovasertib
darovasertib: sourced relationships with 1 company · 5 clinical trials tracked.
darovasertib evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
How could darovasertib → IDYA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | Phase 3 |
Clinical Trial Registry Records (5)
A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Primary endpoint: Median relapse-free survival
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
Primary endpoint: Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)
Primary endpoint: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Primary endpoint: Incidence of Adverse Events (AEs) and significant laboratory abnormalities
A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Primary endpoint: Dose-limiting Toxicity (DLT)
Frequently asked questions
Which companies have sourced relationships with darovasertib?
darovasertib has dated SEC/FDA relationship records for IDEAYA Biosciences, Inc..
How many clinical trials involve darovasertib?
BioSniper tracks 5 clinical trials involving darovasertib.